# Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD

> **NCT01254032** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01254032
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254032, "Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01254032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*